Cholinesterase Inhibitors and Hospitalization for Bradycardia: A Population-Based Study

• Published in: PLoS medicine Vol. 6; no. 9; p. e1000157
• Main Authors: Park-Wyllie, Laura Y., Mamdani, Muhammad M., Li, Ping, Gill, Sudeep S., Laupacis, Andreas, Juurlink, David N.
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 01.09.2009; Public Library of Science (PLoS)
• Subjects: Aged; Aged, 80 and over; Bradycardia - chemically induced; Bradycardia - mortality; Bradycardia - therapy; Canada; Cardiovascular Disorders; Case-Control Studies; Cholinesterase Inhibitors - adverse effects; Cholinesterase Inhibitors - therapeutic use; Dementia - drug therapy; Drug therapy; Female; Hospitalization; Humans; Male; Medical research; Neurological Disorders/Alzheimer Disease; Older people; Studies; Canada; Aged, 80 & over; Canada; Bradycardia; Cholinesterase Inhibitors; Humans; Female; Male; Aged; Hospitalization; Case-Control Studies; Dementia
• ISSN: 1549-1676; 1549-1277; 1549-1676
• DOI: 10.1371/journal.pmed.1000157

Cholinesterase inhibitors are commonly used to treat dementia. These drugs enhance the effects of acetylcholine, and reports suggest they may precipitate bradycardia in some patients. We aimed to examine the association between use of cholinesterase inhibitors and hospitalization for bradycardia. We examined the health care records of more than 1.4 million older adults using a case-time-control design, allowing each individual to serve as his or her own control. Case patients were residents of Ontario, Canada, aged 67 y or older hospitalized for bradycardia between January 1, 2003 and March 31, 2008. Control patients (3:1) were not hospitalized for bradycardia, and were matched to the corresponding case on age, sex, and a disease risk index. All patients had received cholinesterase inhibitor therapy in the 9 mo preceding the index hospitalization. We identified 1,009 community-dwelling older persons hospitalized for bradycardia within 9 mo of using a cholinesterase inhibitor. Of these, 161 cases informed the matched analysis of discordant pairs. Of these, 17 (11%) required a pacemaker during hospitalization, and six (4%) died prior to discharge. After adjusting for temporal changes in drug utilization, hospitalization for bradycardia was associated with recent initiation of a cholinesterase inhibitor (adjusted odds ratio [OR] 2.13, 95% confidence interval [CI] 1.29-3.51). The risk was similar among individuals with pre-existing cardiac disease (adjusted OR 2.25, 95% CI 1.18-4.28) and those receiving negative chronotropic drugs (adjusted OR 2.34, 95% CI 1.16-4.71). We found no such association when we replicated the analysis using proton pump inhibitors as a neutral exposure. Despite hospitalization for bradycardia, more than half of the patients (78 of 138 cases [57%]) who survived to discharge subsequently resumed cholinesterase inhibitor therapy. Among older patients, initiation of cholinesterase inhibitor therapy was associated with a more than doubling of the risk of hospitalization for bradycardia. Resumption of therapy following discharge was common, suggesting that the cardiovascular toxicity of cholinesterase inhibitors is underappreciated by clinicians.